If it wasn't for good news at AstraZeneca this morning, the FTSE 100 would be looking decidedly sick...
If it wasn't for good news at AstraZeneca this morning, the FTSE 100 would be looking decidedly sick for the start of this week's trading. AstraZeneca has leapt 281p or 13.6% to £23.49 within the first hour of trading after a US judge upheld patents on its ulcer drug, Prosilec, boosting confidence that the pharmaceutical does a case to fight when rival companies make cheap generic copies of a drug. But the FTSE 100 rose just 2.50 points or 0.06% to 3955.90 in early trading, suggesting the market is facing another tough day. Of those companies that have climbed, Abbey National...
To continue reading this article...
Join Professional Adviser for free
Signup and gain exclusive members-only insights
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes
